MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Northwell Health

Status: Completed

Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Pulmonary Arterial Hypertension

Study type: Observational

Funder types: Other

Identifiers

NCT02858791

13-003A

Details and patient eligibility

About

The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.

Full description

The investigators will test our hypothesis and accomplish our objectives by pursuing three Specific Aims:

To investigate the interrelationship between macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH with a working hypothesis that an increased release of MIF into the pulmonary vasculature during cardiopulmonary exercise changes the normal balance between plasma MIF and T4.

Enrollment: 99 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject must be at least 18 years of age and have confirmed pulmonary hypertension (PH) and interstitial lung disease (ILD).
• ILD was identified on high resolution computed tomography along with a total lung capacity (TLC) <70% of predicted value on pulmonary function tests (PFTs) with no evidence of pulmonary hypertension on echocardiogram.
• PAH group patients were defined as patients with a mean pulmonary artery pressure >25 mmHg at rest and a wedge pressure of <15 mmHg (millimeters of mercury), measured by right heart catheterization (WHO group I PAH).
• PH+ILD group, subjects with evidence of ILD on high resolution CT Scan and mean pulmonary artery pressure >25 mmHg on right heart catheterization.
• Patient with evidence of Chronic thromboembolic disease on CT angiogram and mean pulmonary artery pressure >25mmHg on right heart catheterization. (WHO group IV)
• Patient with Pulmonary Hypertension due to other conditions, such as Sarcoidosis, Gauchers disease, Hemolytic Anemia and Myeloproliferative disorders.
• Normal control group: Subjects without cardiopulmonary disease, with a normal PFT and ECG.

Exclusion criteria

• Failure to obtain informed consent;
• Pregnancy
• Subjects with cardiopulmonary disease other than PH and ILD;
• Unexplained abnormal PFT, ECG, Routine blood/chemistries test
• History or existing other sever organ/system diseases
• Defined Acute pulmonary embolism
• Age < 18 years

Trial design

99 participants in 2 patient groups

Healthy Controls

Description:

Subjects are made up of healthy adults Interventions: Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test

Affected

Description:

Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease Interventions: Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test